(MDRX) Veradigm - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US01988P1084

MDRX: Practice Management, Revenue Cycle, EHR, Patient Engagement, API Solutions

Veradigm Inc. (NASDAQ:MDRX), a healthcare technology company, delivers comprehensive IT solutions to healthcare providers, payers, and biopharma markets in the U.S. and internationally. The company provides a suite of tools for healthcare providers, including Practice Management software, AI-driven Patient Scheduling, Electronic Statements and Payments, and Revenue Cycle Management solutions. Its EHR offerings include ePrescribe with EPCS, Veradigm EHR, and Practice Fusion EHR, alongside a Patient Engagement Platform. The company also offers API connectivity solutions like Veradigm Connect and Veradigm App Expo, as well as a Channel Partner Program and Veradigm ePrescribe Enterprise for network partners.

For health plans and payers, Veradigm provides risk adjustment solutions such as Health Equity Analytics, Risk Adjustment Analytics, and Utilization Analytics. It also offers quality management solutions, data exchange and coding tools like eChart Courier and eChart Coder, and Veradigm Payer Insights. The company serves biopharma with real-world data solutions, including health data sets and registries, real-world evidence platforms, and therapy-focused solutions for cardiovascular, CNS, metabolic, and immunology data. Additionally, it provides Digital Health Media solutions. Formerly known as Allscripts Healthcare Solutions, Inc., the company rebranded as Veradigm Inc. in January 2023. Founded in 1986, it is headquartered in Chicago, Illinois.

3-Month Forecast: Based on , MDRX has shown declining momentum, with its SMA 20 (5.33) and SMA 50 (7.60) below the SMA 200 (9.08), indicating a bearish trend. Average volume of 825,050 shares suggests moderate liquidity. With an ATR of 0.65, price fluctuations are expected to remain controlled. Support levels may form near $4.20, while resistance could cap upside at $6.00. From a perspective, the P/S ratio of 0.36 and P/B of 0.87 suggest undervaluation, potentially attracting value investors. However, the forward P/E of 15.17 indicates cautious sentiment. Overall, MDRX is likely to trade sideways with a slight bearish bias in the near term.

Additional Sources for MDRX Stock

MDRX Stock Overview

Market Cap in USD 576m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Technology
IPO / Inception 1999-07-26

MDRX Stock Ratings

Growth 5y -5.50%
Fundamental -
Dividend 0.30%
Rel. Strength Industry -35.3
Analysts 3.75/5
Fair Price Momentum 5.04 USD
Fair Price DCF 14.53 USD

MDRX Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y 0.00%
Payout Consistency 1.0%

MDRX Growth Ratios

Growth Correlation 3m -85.9%
Growth Correlation 12m -0.1%
Growth Correlation 5y -23.7%
CAGR 5y 0.98%
CAGR/Max DD 5y 0.01
Sharpe Ratio 12m -0.07
Alpha -39.74
Beta 0.12
Volatility 45.79%
Current Volume 7.7k
Average Volume 20d 114.8k
What is the price of MDRX stocks?
As of March 16, 2025, the stock is trading at USD 5.45 with a total of 7,700 shares traded.
Over the past week, the price has changed by +5.21%, over one month by +1.87%, over three months by -44.16% and over the past year by -34.73%.
Is Veradigm a good stock to buy?
Neither. Based on ValueRay Analyses, Veradigm is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of -5.50 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MDRX as of March 2025 is 5.04. This means that MDRX is currently overvalued and has a potential downside of -7.52%.
Is MDRX a buy, sell or hold?
Veradigm has received a consensus analysts rating of 3.75. Therefor, it is recommend to hold MDRX.
  • Strong Buy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • Strong Sell: 0
What are the forecast for MDRX stock price target?
According to ValueRays Forecast Model, MDRX Veradigm will be worth about 5.4 in March 2026. The stock is currently trading at 5.45. This means that the stock has a potential downside of -0.18%.
Issuer Forecast Upside
Wallstreet Target Price 10.5 92.7%
Analysts Target Price 12.8 133.9%
ValueRay Target Price 5.4 -0.2%